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a  b  s  t  r  a  c  t
After  the  Food  and  Drug  Administration  (FDA)  licensed  quadrivalent  human  papillomavirus  vaccine
(HPV4)  in  2006,  reports  suggesting  a possible  association  with  venous  thromboembolism  (VTE)  emerged
from  the  Vaccine  Adverse  Event  Reporting  System  and  the Vaccine  Safety  Datalink.  Our objective  was  to
determine  whether  HPV4  increased  VTE  risk.
The  subjects  were  9−26-year-old  female  members  of ﬁve  data  partners  in  the  FDA’s  Mini-Sentinel
pilot project  receiving  HPV4  during  2006−2013.  The  outcome  was  radiologically  conﬁrmed  ﬁrst-ever
VTE  among  potential  cases  identiﬁed  by diagnosis  codes  in administrative  data  during  Days  1−77  after
HPV4  vaccination.  With  a self-controlled  risk  interval  design,  we  compared  counts  of ﬁrst-ever  VTE in
risk intervals  (Days  1−28  and  Days  1−7 post-vaccination)  and  control  intervals  (Days  36−56  for  Dose  1
and  Days  36−63  for Doses  2 and  3). Combined  hormonal  contraceptive  use  was  treated  as  a potential
confounder.  The  main  analyses  were:  (1)  unadjusted  for time-varying  VTE  risk from  contraceptive  use,
(2) unadjusted  but  restricted  to cases  without  such  time-varying  risk,  and  (3)  adjusted  by incorporating
the  modeled  risk  of  VTE  by week  of contraceptive  use  in  the  analysis.
Of 279  potential  VTE  cases  identiﬁed  following  1,423,399  HPV4  doses  administered,  225  had  obtainable
charts,  and 53  were  conﬁrmed  ﬁrst-ever  VTE.  All  30 with onsets  in risk  or control  intervals  had  known
risk  factors  for  VTE.  VTE  risk  was  not  elevated  in  the  ﬁrst  7 or 28  days  following  any  dose  of  HPV  in any
analysis  (e.g.  relative  risk  estimate  (95%  CI) from  both  unrestricted  analyses,  for  all-doses,  28-day  risk
interval:  0.7  (0.3−1.4)).  Temporal  scan  statistics  found  no  clustering  of VTE  onsets  after  any  dose.
Thus, we found  no  evidence  of  an  increased  risk  of  VTE  associated  with  HPV4  among  9−26-year-old
females.  A  particular  strength  of this  evaluation  was  its  control  for both  time-invariant  and  contraceptive-
related  time-varying  potential  confounding.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND∗ Corresponding author at: Harvard Pilgrim Health Care Institute and Department
f  Population Medicine, Harvard Medical School, Landmark Center, 401 Park Dr.,
uite  401, Boston, MA  02215-3920, USA.Tel.: +1 617 509 9822;
ax: +1 617 509 9845.
E-mail address: katherine yih@harvardpilgrim.org (W.K. Yih).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.087
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In June 2006, the Food and Drug Administration (FDA) approved
the quadrivalent human papillomavirus vaccine (HPV4; Gardasil;
Merck) for the prevention of anogenital cancers, associated precan-
cerous lesions, and genital warts caused by human papillomavirus
types 6, 11, 16, and 18. HPV4 is routinely recommended as a
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
VTE case validation criteria [13].
Pulmonary Embolism Deep Vein Thrombosis
Deﬁnite Conﬁrmed by pulmonary
angiography, spiral CT
scan/CT pulmonary
angiography, MRI  scan, or
pathology
Conﬁrmed by venography,
compression/duplex
ultrasound, CT scan, MRI
scan, or at autopsy
Probable If above tests not
performed, or were
indeterminate, but
ventilation-perfusion scan
ﬁndings were of high
probability
If above tests not
performed, or were
indeterminate, but
impedance
plethysomography,
radionuclide venography,
or radiolabelled ﬁbrinogen
scan test results were
reported as positive
Possible If all of the above tests
were not performed, or
were indeterminate, and
two of the following
criteria were satisﬁed:
medical record indicates
physician-diagnosed PE,
signs or symptoms of PE
were documented, and the
patient underwent therapy
If all of the above tests
were not performed, or
were indeterminate, and
two of the following
criteria were satisﬁed:
medical record indicates
physician-diagnosed DVT,
signs or symptoms of DVT
were documented, and the
patient underwent therapyW.K. Yih et al. / Vac
hree-dose series (0, 1−2, and 6 months) for those aged 11–12 years
ut can be administered as young as age 9 years; catch-up vacci-
ation is recommended for females aged 13–26 years and males
ged 13–21 years who have not been previously vaccinated [1].
o safety issues were identiﬁed in pre-licensure studies involving
pproximately 21,000 subjects aged 9–26 years [2].
Post-licensure surveillance identiﬁed a possible increased risk
f venous thromboembolism (VTE) after HPV4 vaccination. In the
rst 2.5 years of passive surveillance in the Vaccine Adverse Events
eporting System (VAERS), VTE was reported more frequently fol-
owing HPV4 than expected using other vaccines for comparison
3]. However, 90% of the reported cases had at least one pre-
xisting known risk factor, and most of the comparison vaccines
ere childhood vaccines, suggesting that the prevalence of VTE
isk factors among adolescents may  have explained the dispropor-
ionate reporting. To supplement passive surveillance, in the ﬁrst
 years after licensure, the Vaccine Safety Datalink (VSD) mon-
tored 600,558 HPV4 doses administered to females aged 9–26
ears, checking for increased risks of eight outcomes using sequen-
ial analysis methods [4]. No safety signals were detected. However,
here was a statistically non-signiﬁcant relative risk of 1.98 for VTE
fter HPV4 administration among females aged 9–17 years using a
istorical comparison group. (If the incidence of adolescent VTE has
een increasing [5], historical controls could have produced bias.)
he eight post-HPV4 VTE cases producing this estimate were chart-
eviewed, and ﬁve were conﬁrmed. The VTE diagnosis in four of the
ve conﬁrmed cases occurred within 7 days after vaccination; the
fth occurred on Day 32. All ﬁve cases had at least one known risk
actor—contraceptive use, coagulation disorders, smoking, obesity,
r prolonged hospitalization. No elevated risk was  detected after
PV4 vaccination among females aged 18–26 years.
In December 2010, this information was presented to the FDA
ediatric Advisory Committee as part of a routine safety review [6].
he committee recommended that additional surveillance stud-
es be conducted to further evaluate the risk of VTE, leading to
he current study by the Mini-Sentinel/Post-licensure Rapid Immu-
ization Safety Monitoring (PRISM) program [7]. Our objective was
o evaluate the risk of VTE following HPV4 vaccination, considering
he role of combined hormonal contraceptives (called “contracep-
ives” below) as a potential confounder or effect modiﬁer.
Three studies ﬁnding no association between HPV4 and VTE
ere published after the launch of our investigation [8–10]. These
re discussed later.
. Methods
.1. Study population and data sources
The study population consisted of female HPV4 vaccinees
–26 years of age from ﬁve Mini-Sentinel Data Partners (Aetna,
ealthCore, Humana, Optum, and Tennessee Medicaid) during a
aximum period of June 2006−June 2013. Inclusion required con-
inuous enrollment, with medical and pharmacy coverage, from 4
onths before through at least 70 days after the ﬁrst dose of HPV4.
Sources of immunization records were claims data from the Data
artners and data from eight participating state/city immuniza-
ion registries. The source of VTE diagnosis records was insurance
laims. Medical records were used to conﬁrm both HPV4 exposure
nd VTE outcome.
.2. Study design and null hypothesisA self-controlled risk interval (SCRI) design [11,12] was used.
his design uses only vaccinated cases occurring in a pre-speciﬁed
isk or comparison interval, and it controls for all potentialwith anticoagulants, or an
IVC ﬁlter was placed
with anticoagulants, or an
IVC ﬁlter was placed
time-invariant confounders, e.g. genetic factors. Days 1−28 post-
vaccination was  chosen as the primary risk interval and Days
1−7 as the secondary risk interval. The comparison (“control”)
interval, considered unexposed, was  designated as Days 36−56
post-vaccination for Dose 1 and Days 36−63 for Doses 2 and 3.
The control interval for Dose 1 was  speciﬁed to end earlier to avoid
potential bias due to Dose 2 frequently being given during Days
57−63 after Dose 1.
The null hypothesis was  that the average daily risk of VTE onset
during the risk interval was the same as during the control interval.
2.3. Exposures
HPV4 vaccination was identiﬁed by means of CPT code 90649
and CVX code 62. Both administrative and medical record data were
used to establish HPV4 timing and dose number.
2.4. Outcomes
We used ICD-9 codes 415.1x (pulmonary embolism, and infarc-
tion), 451.x (phlebitis, and thrombophlebitis), and 453.x (other
venous embolism, and thrombosis) associated with claims in out-
patient, emergency department, and inpatient settings to identify
potential cases of VTE. We  considered only the ﬁrst VTE diagnosis
found in a patient’s claims since enrollment and excluded potential
cases with a history of VTE by chart review.
VTE cases were classiﬁed using the criteria developed by the
Worcester Venous Thromboembolism Study (Table 1) [13]. The
main analyses were conducted using only deﬁnite, i.e. radiolo-
gically conﬁrmed, VTE cases. Probable and possible cases were
included in secondary analyses. In all analyses, adjudicated symp-
tom onset dates were used, not VTE diagnosis dates based on claims
data.2.5. VTE risk factors
We collected data from both claims and medical records on
potential cases’ VTE risk factors for descriptive purposes and to
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xplore their role as possible effect modiﬁers of the HPV4−VTE
elationship.
Contraceptive use is estimated to increase VTE risk 3–6-fold
ue to an estrogen-mediated procoagulant state [14]. Some studies
ave shown a higher risk in the ﬁrst year of use [15,16], especially in
he ﬁrst 3 months. To control for the confounding effect of contra-
eptive use and also to assess whether such use could be an effect
odiﬁer of the association between HPV4 and VTE, the contracep-
ive use status of all cases was determined using National Drug
odes and Data Partners’ “homegrown” codes.
Cases were considered exposed to contraceptives if the dispens-
ng date in the claims data plus total days supplied included the
ate of the HPV4 dose of interest or any time through the end of
he control interval after that dose.
Information on contraceptive usage found in the medical
ecords was used to supplement the claims data in determining
ontraceptive initiation, duration, and product.
.6. Statistical analyses
The three co-primary analyses used the SCRI design [11,12].
Analysis #1 included all HPV4 recipients with VTE onset in either
he risk or the control interval after an HPV4 dose. It did not adjust
or any variation in contraceptive-associated VTE risk that might
ave existed between risk and control intervals due to recent initi-
tion of contraceptive use.
Analysis #2 was restricted to vaccinees whose baseline risk of
TE was unlikely to have varied between the risk and control inter-
als due to contraceptive use, i.e. (1) those vaccinees who  had no
ecord of contraceptive use as of the last day of the control interval
nd (2) those vaccinees who had been on contraceptives continu-
usly for at least 9 months (see below) as of the day of the HPV4
ose.
Analysis #3 included the same cases as Analysis #1 but explic-
tly adjusted for the changing risk of VTE associated with the ﬁrst 9
onths of contraceptive use (see below). In the logistic regression
nalysis, offset terms were used for vaccinees who initiated contra-
eptives between 8.99 months prior to the HPV4 dose and the end
f the control interval, as inferred from the pharmacy dispensing
ata and the medical record.
To obtain the offset terms for Analysis #3, the risk of ﬁrst-ever
TE by duration of contraceptive use was estimated from a risk
urve generated from electronic claims data from 9−26-year-old
emales who had a minimum of 7 months of continuously enrolled
ime during a maximum period of May  2004−June 2013. Only
erson-days prior to the ﬁrst initiation and during the ﬁrst con-
raceptive span contributed to the risk curve. Potential VTE cases
ithin 1−28 days following HPV4 were excluded. We  used Poisson
egression and ﬁt the VTE risk by contraceptive duration (as well
s secular month), using progressively higher-order polynomial
unctions until no statistical signiﬁcance was found. Age, estrogen
osage, and Data Partner were categorical variables in the model.
erms for plausible interactions were introduced one by one into
he modeling to check for effect modiﬁcation. Goodness-of-ﬁt was
etermined based on the log-likelihood ratio, p-values of model
arameters, Akaike information criterion, and biologic plausibility.
isual inspection of the data together with explorations early in
odel-building indicated that the risk of VTE during the 9–11.99
onths after contraceptive initiation was approximately the same
s the risk at ≥ 12 months. Therefore, the VTE risk was  considered
o plateau starting at 9 months of contraceptive usage.
For Analysis #3, prior to any analysis of the HPV4−VTE
ssociation, two sets of offset terms were obtained from the
ontraceptive-VTE model that was ultimately selected—one for the
8-day risk interval and the other for the 7-day risk interval. First,
or each case, we solved the regression equation from the model to4 (2016) 172–178
determine baseline VTE risk by week during the observation period
after HPV4 vaccination. Then, using the predicted values for each
week after vaccination for each case, we  calculated (for each of the
two risk intervals) the area under the contraceptive-VTE risk curve
for the risk-interval segment of time as a proportion of the summed
areas under the curve for the risk- and control-interval segments of
time. We  then used that proportion, p (equivalent to the probabil-
ity of the case being in the risk interval under the null hypothesis
of no association between HPV4 and VTE), and calculated ln(p/(1-
p)), which served as the offset term for the case and risk interval in
question.
Four sets of secondary SCRI analyses were carried out. First, we
repeated the analyses, also including the probable and possible VTE
cases. Second, we  explored the possibility of effect modiﬁcation by
age by repeating Analyses #1 and #3 with age as an interaction term
in the model. Third, we checked for possible effect modiﬁcation by
VTE risk factor group by including each of the risk factor groups
(as yes/no categorical variables) one by one as interaction terms in
the model and repeating Analysis #3. Finally, to address possible
concerns that the 28-day risk interval was  too short, we repeated
Analyses #1-#3 using a Days 1–35 risk interval, ﬁrst calculating
offset terms for this new risk interval.
To check for possible clustering of VTE onsets in the observation
period after HPV4 vaccination, we used the temporal scan statistic
[17,18], a self-controlled design. For Dose 1 and all-doses analy-
ses, we included the deﬁnite VTE cases with onset of symptoms
1−56 days after vaccination. For analyses of Doses 2 and 3, we used
the deﬁnite cases with onsets 1−63 days after vaccination. Using
the SaTScan software [19], we  evaluated all potential intervals of
increased risk up to 50% of the respective periods, with adjustment
for the multiple testing involved.
2.7. Chart validation
Charts for both vaccination and VTE visits were sought for poten-
tial cases with ﬁrst-ever VTE diagnoses occurring 1−77 days after
a dose of HPV4. (Fourteen days were added to the 63 days in the
main observation period in case of delays between symptom onset
and date of VTE diagnosis.) A board-certiﬁed pediatric hematolo-
gist, blinded to the timing of HPV4 vaccination, adjudicated the VTE
cases, reviewing medical records, noting or estimating the date of
symptom onset, and classifying potential cases as deﬁnite, proba-
ble, possible, or not-VTE.
The positive predictive value of the VTE identiﬁcation algorithm
was determined by dividing the number of VTE cases classiﬁed
as deﬁnite ﬁrst-ever VTE by the total number of potential cases
identiﬁed electronically for which VTE charts were obtained.
3. Results
The study included 1,423,399 doses of HPV4 vaccine adminis-
tered, of which 650,475 (46%) appeared to be ﬁrst doses, 489,737
(34%) second doses, and 283,187 (20%) third doses.
The total number of potential ﬁrst-ever VTE cases diagnosed
within 77 days after a dose of HPV4 vaccine, as ascertained in the
electronic claims data, was 279. Charts to conﬁrm/rule out VTE
were obtained for 225 of these; 53 were classiﬁed as deﬁnite, ﬁrst-
ever VTE (Fig. 1), for a positive predictive value of 24%. (Omitting
the ambulatory care setting and ICD-9 code 451.x (phlebitis and
thrombophlebitis) from the algorithm would have increased this
to 65% but at the cost of missing 10 (19% of) conﬁrmed cases [20].)
Of the 53 conﬁrmed cases, 30 had adjudicated onset of symptoms
in the risk or control interval after a HPV4 dose and were used in
the main SCRI analyses, while ﬁve had onset prior to vaccination
and 12 had onset after the control interval and were excluded. Six
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279 po tenal VTE cases ascertained
54 with unobtainable VTE charts
225 with VTE info ob tained
97 ruled out based on  ne gave test results 
or cl ear  miscoding
128 to adjudica on
53 deﬁnite 1 probable 6 possible 2 disqualiﬁed—
history of VTE
66 ruled out
prio r to HPV4
in Days 1-28 post-HPV4 (1° risk interval)
in Days 29-35 po st-H PV4 (washout period)
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fig. 1. Disposition of potential ﬁrst-ever VTE cases within 77 days after HPV4 vaccin
laims  data. The numbers below the vertical arrows show the temporal distribution
Control interval” refers to Days 36−56 after Dose 1 and Days 36−63 after Doses 2 
f the 53 deﬁnite cases had onset of symptoms in the Days 29−35
eriod. These were included in sensitivity SCRI analyses as well as
n the temporal scan statistical analyses. An additional three proba-
le or possible cases had onset in risk or control intervals and were
ncluded in sensitivity SCRI analyses.
Among the 30 deﬁnite VTE cases included in the main analy-
es, the most frequent risk factor groups were contraceptive use
23); hypercoagulable states and coagulation defects (16); and
ransplant, surgery, venous catheterization, and other immobil-
ty conditions (12) (Table 2). The number of risk factor groups per
atient ranged from 1 to 5 per patient: no patients had 0, 3 patients
ad 1, 10 had 2, 10 had 3, 5 had 4, and 2 had 5.
Approximately 9,000 potential cases of VTE in roughly 12
illion person-years were included in the contraceptive-VTE mod-ling. Ultimately, and prior to any analysis of the HPV4-VTE
ssociation, a model including Data Partner (ﬁve levels), contracep-
ive use (yes/no), estrogen dose (high/low), age group (six levels),
able 2
TE risk factors identiﬁed among the 30 deﬁnite VTE cases in the self-controlled
isk interval analyses. Presence of risk factors was determined from claims and/or
edical record data.
Group no. Risk factor (RF) group description No. of deﬁnite VTE
cases with RF group
11 Contraceptive use 23
1  Hypercoagulable states and
coagulation defects
16
5  Transplant, surgery, venous
catheterization, other immobility
conditions
12
8  Obesitya 10
2  Cancer, inﬂammatory conditions,
infection
7
3 Cardiovascular conditions 4
13  Family history of VTE 4
10  Tobacco use 3
12  Thoracic outlet syndrome 2
7  Sickle cell anemia 1
9  Renal conditions 1
4  Cardiac conditions 0
6  Pregnancy 0
a Obesity was  deﬁned as BMI  ≥ 30 for adults (≥ 18) [21] and BMI  ≥ 95 percentile
or youth (< 18) [22].. The potential cases were identiﬁed by means of an algorithm applied to electronic
sets of the respective type of case (deﬁnite, etc.) with respect to HPV4 vaccination.
secular month (continuous, modeled as a linear function), weeks on
contraceptives (continuous, modeled as a cubic function (Fig. 2)),
and two  interaction terms—age in years × contraceptive status and
Data Partner × secular month—was selected as the most appropri-
ate, based on statistical and biological criteria.
None of the three co-primary analyses demonstrated any asso-
ciation between HPV4 and VTE, regardless of dose number or risk
interval (Table 3). The contraceptive-adjusted results for the unres-
tricted group (bottom third of the table) were very similar to the
unadjusted results for the same group (top third), with a risk esti-
mate for all-doses, with 28-day risk interval, of 0.7 (95% CI: 0.3,
1.4). The second of the three approaches, restricted to patients
determined to have no time-varying risk due to contraceptives,
had comparatively few cases (middle third), leading to wider con-
ﬁdence intervals.
None of the secondary analyses produced statistically signiﬁcant
results.
The temporal distribution of onsets of deﬁnite VTE cases from
Day 1 post-vaccination through the last day of the respective con-
trol interval is shown in Fig. 3. None of the temporal scan statistical
tests conducted for Doses 1, 2, 3, or all doses combined detected any
statistically signiﬁcant clustering of post-vaccination onset tim-
ing (e.g. in all-doses analysis, most likely cluster was Days 48−49,
p  = 0.26).
4. Discussion
In this self-controlled study comprising more than 1.4 million
doses of HPV4 among more than 650,000 9−26-year-old females in
the USA, we  found no evidence of an increased risk of VTE. None of
the three co-primary analyses or the secondary analyses produced
statistically signiﬁcant results for any of the doses or risk inter-
vals. Likewise, the temporal scan statistical test did not detect any
temporal clustering of VTE onsets in the 8−9 weeks after HPV4 vac-
cination. This result, along with the ﬁnding of no increased risk in
the sensitivity SCRI analyses using a Days 1–35 risk interval, provide
reassurance that we  did not miss an increased risk due to misspec-
ifying the risk interval, which could have included time beyond our
primary 28-day risk interval.
The strengths of our study are its size, the self-controlled design
used to control for time-invariant confounding, the adjustment for
potential time-varying confounding from contraceptive use, the
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Fig. 2. Predicted VTE incidence by week in the year after combined hormonal contraceptive initiation. The curve of predicted VTE incidence obtained by modeling VTE risk
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Cy  duration of contraceptive use is a cubic function to Week 39 (9 months) of cont
or  calculating offset terms for the contraceptive-adjusted Analysis #3. Week 0 re
ispensing), and so on.
ssessment of possible effect modiﬁcation by age and VTE risk fac-
ors, the use of chart review to validate both cases and exposures,
nd the use of the temporal scan statistic to supplement the main
nalyses. The shape of the risk curve of VTE by contraceptive dura-
ion obtained from modeling and used for the adjustment of the
PV4−VTE analysis (Analysis #3) was consistent with what has
een reported in the literature [15].
Given the control for confounding and other strengths of our
tudy, we consider our null results to be more credible than
able 3
ase counts and relative risk estimates for the three co-primary self-controlled risk inter
Dose Days in risk interval Cases in risk interval Cases in control in
1. Analyses with all deﬁnite VTE cases, with no adjustment for contraceptive use
1  1−28 4 5 
2  1−28 4 8 
3  1−28 5 4 
All  1−28 13 17 
1  1−7 0 5 
2  1−7 1 8 
3  1−7 1 4 
All  1−7 2 17 
2.  Analyses with deﬁnite VTE cases, restricted to those with either no contraceptive use or e
1  1−28 0 3 
2  1−28 1 2 
3  1−28 4 2 
All  1−28 5 7 
1  1−7 0 3 
2  1−7 0 2 
3  1−7 0 2 
All  1−7 0 7 
3.  Analyses with all deﬁnite VTE cases, with adjustment for contraceptive use
1  1−28 4 5 
2  1−28 4 8 
3  1−28 5 4 
All  1−28 13 17 
1  1−7 0 5 
2  1−7 1 8 
3  1−7 1 4 
All  1−7 2 17 ive duration, after which the risk was determined to plateau. The model was used
nts the ﬁrst week of contraceptive use (Days 0−6, where Day 0 is the day of the
the association suggested by the VAERS study that found dis-
proportionate reporting of venous thromboembolic events [3].
Considering that VSD saw an elevated (albeit not statistically sig-
niﬁcant) risk estimate for 9−17 year olds but not for 18−26 year
olds [4], we  checked to see if the risk of VTE after HPV4 vaccination
varied with age at vaccination and found no evidence of such effect
modiﬁcation by age. Indeed, of the 10 deﬁnite cases aged 9−17
years, 4 occurred in the 28-day risk interval and six in the control
interval (Table 4).
val analyses.
terval Relative risk 95% CI lower bound 95% CI upper bound
0.60 0.15 2.27
0.50 0.13 1.59
1.25 0.33 5.05
0.70 0.33 1.44
0 − −
0.50 0.03 2.73
1.00 0.05 6.76
0.43 0.07 1.51
lse long-term contraceptive use
0 – –
0.50 0.02 5.22
2.00 0.39 14.42
0.66 0.20 2.08
0 − –
0 − –
0 − –
0 − –
0.61 0.15 2.32
0.47 0.13 1.50
1.29 0.34 5.21
0.70 0.33 1.43
0 − −
0.47 0.03 2.55
1.09 0.06 7.38
0.43 0.07 1.50
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Rig. 3. Temporal distribution of onsets of deﬁnite VTE cases after HPV4 vaccinatio
espective control interval for HPV4 Doses 1, 2, and 3. The 10 cases with onsets in D
nsets  in Days 1−63 after Dose 3 were included in the temporal scan statistical anaThe lack of association we found is consistent with the results
f three more recent studies, which used longer risk intervals. The
rst, an FDA post-market commitment study, used a SCRI design
ith two alternative risk intervals, Days 1−14 and Days 1−60, and
able 4
isk factor groups and other characteristics of the 33 deﬁnite, probable, or possible cases
Case # Age group Case status HPV4 dose
preceding VTE
onset
Number of days
from HPV4 dose to
VTE onset
VT
gro
1 12−14 Deﬁnite 3 16 
2  12−14 Deﬁnite 3 36 
3  15−17 Deﬁnite 1 25 
4  15−17 Deﬁnite 1 26 
5  15−17 Deﬁnite 1 43 
6  15−17 Deﬁnite 1 51 
7  15−17 Deﬁnite 2 49 
8  15−17 Deﬁnite 2 62 
9  15−17 Deﬁnite 3 26 
10  15−17 Deﬁnite 3 48 
11  18−20 Deﬁnite 1 37 
12  18−20 Deﬁnite 2 5 
13  18−20 Deﬁnite 2 10 
14  18−20 Deﬁnite 2 21 
15  18−20 Deﬁnite 2 21 
16  18−20 Deﬁnite 2 43 
17  18−20 Deﬁnite 2 60 
18  18−20 Deﬁnite 2 63 
19  18−20 Deﬁnite 3 3 
20  18−20 Deﬁnite 3 57 
21  21−23 Deﬁnite 1 17 
22  21−23 Deﬁnite 1 41 
23  21−23 Deﬁnite 1 48 
24  21−23 Deﬁnite 2 47 
25  21−23 Deﬁnite 2 58 
26  24−26 Deﬁnite 1 17 
27  24−26 Deﬁnite 2 49 
28  24−26 Deﬁnite 3 15 
29  24−26 Deﬁnite 3 17 
30  24−26 Deﬁnite 3 48 
31  21−23 Probable 2 24 
32  15−17 Possible 3 63 
33  21−23 Possible 3 36 
a Key to risk factor groups is in Table 2. Contraceptive use is shown in next column inst
b Positive numbers indicate contraceptive use started prior to index dose of HPV4.
c Those with unknown duration of contraceptive use were included in analysis and tre possible range extended from Day 1 post-vaccination through the last day of the
56 after Dose 1, 14 cases with onsets in Days 1−63 after Dose 2, and 12 cases withincluded approximately 190,000 females in Kaiser Permanente in
California who  had received at least one dose of HPV4. No increased
risk of venous embolism, thromboembolic events, or other clot-
ting disorders was  observed [8]. The second was a cohort study
 in risk and control intervals.
E risk factor
upsa
Contraceptive
use
HPV4 vaccination date
minus contraceptive
start date (days)b
Contraceptive
time-varying
riskc
1, 2, 5 No No
1, 5 No No
1, 2, 8, 13 Yes 12 Yes
8, 13 Yes 0 Yes
1 Yes 47 Yes
5 No No
1, 3, 8 Yes 60 Yes
1, 12 Yes 259 Yes
1, 8 Yes (Long-term) No
1, 2, 3, 5, 9 No No
5, 8, 10 Yes Unknown Unknown
Yes 71 Yes
5 Yes (Long-term) No
1 Yes 62 Yes
1 Yes 94 Yes
1 Yes 75 Yes
2, 5 No No
3, 8 Yes Unknown Unknown
5, 13 Yes -3 Yes
5, 12 Yes -3 Yes
1, 5, 8 Yes 26 Yes
2, 5, 8 Yes (Long-term) No
1, 2, 3, 7 No No
2, 10 Yes (Long-term) No
1 Yes 101 Yes
5, 8 Yes 226 Yes
1, 13 Yes 166 Yes
8 No No
10 Yes (Long-term) No
1 Yes Unknown Unknown
Yes -1 Yes
Yes -15 Yes
5, 8 Yes 181 Yes
ead.
ated as though they had no time-varying risk from contraceptive use.
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omprising more than 696,000 doses of HPV4 administered to
emales in Denmark and Sweden. No increased risk of VTE was  seen
sing a risk interval of 1−90 days after vaccination (rate ratio 0.86
95% CI: 0.55−1.36)) [9]. The third used a self-controlled case series
esign and studied a population of Danish females; 500,345 of these
ad received HPV4. Using a post-vaccination risk interval of 1−42
ays, the investigators found an incidence ratio of 0.77 (95% CI:
.53−1.11) [10].
One limitation of our study was the possibility of misclassi-
cation of contraceptive duration in the contraceptive-adjusted
nalysis (Analysis #3). However, it seems unlikely that any con-
istent bias was introduced by such misclassiﬁcation. Also, charts
ould not be obtained for about one-ﬁfth of the potential cases iden-
iﬁed by the algorithm, reducing our statistical power. Finally, in
ight of the fact that there were at most 30 deﬁnite VTE cases in
isk and control intervals, the analyses of effect modiﬁcation by age
nd VTE risk factors, which all produced null results, may  have had
imited power to detect true effect modiﬁcation of the HPV4−VTE
elationship by these factors.
. Conclusions
We  found no evidence of an increased risk of VTE associated
ith HPV4 vaccination among 9−26-year-old females in this study
omprising more than 1.4 million doses of HPV4 administered.
hese results, together with those of three recent studies, provide
eassurance about the safety of HPV4 with respect to VTE. Partic-
lar strengths of our study were the self-controlled design, which
ontrolled for time-invariant confounding, and the adjustment for
otential time-varying confounding from contraceptive use.
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